Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | ELANE | P08246 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15600776 | 0.98 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4BTK | |
| SCHEMBL17120421 | 0.96 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4BTK | |
| SCHEMBL14079970 | 0.85 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4BTK | |
| SCHEMBL16665089 | 0.85 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 | |
| SCHEMBL25765941 | 0.83 | KMT2A (0.38) | BTKELANEMEN1CYP2C19KMT2A | |
| SCHEMBL14079971 | 0.83 | MEN1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4BTK | |
| SCHEMBL27451922 | 0.83 | MEN1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4BTK | |
| SCHEMBL27451925 | 0.83 | MEN1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4BTK | |
| SCHEMBL16665575 | 0.83 | GAA (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4BTK | |
| SCHEMBL25583715 | 0.82 | EGFR (0.33) | BTKELANEMEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265616-A1 | SPIROCYCLIC COMPOUND AS KRAS-G12C INHIBITOR | Shanghai Euregen Biopharma Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022111521-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州多域生物技术有限公司 | 2022-06-02 | — | — | WO | disclosed |
| EP-3268000-B1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-08-04 | — | — | EP | disclosed |
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | CHRNB2 4702/4885CHRNB4 4752/4885CHRNA3 4829/4885 |
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | CHRNB2 4844/4885CHRNB4 4764/4885CHRNA3 4763/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CHRNB2 4883/4885CHRNB4 4876/4885CHRNA3 4871/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | CHRNB2 4831/4885CHRNB4 4846/4885CHRNA3 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.